{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T07:17:23Z","timestamp":1777792643806,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bone"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1016\/j.bone.2004.01.008","type":"journal-article","created":{"date-parts":[[2004,5,4]],"date-time":"2004-05-04T10:14:26Z","timestamp":1083665666000},"page":"890-899","source":"Crossref","is-referenced-by-count":145,"title":["Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis"],"prefix":"10.1016","volume":"34","author":[{"given":"R","family":"Recker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A","family":"Stakkestad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"C.H","family":"Chesnut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Skag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Hoiseth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Ettinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Mahoney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.C","family":"Schimmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.D","family":"Delmas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2004.01.008_BIB1","unstructured":"International Osteoporosis Foundation. Annual Report; 2000."},{"key":"10.1016\/j.bone.2004.01.008_BIB2","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","article-title":"Systematic review of the associations between dose regimens and medication compliance","volume":"23","author":"Claxton","year":"2001","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bone.2004.01.008_BIB3","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S8756-3282(99)00273-2","article-title":"Intermittent versus continuous clodronate administration in postmenopausal women with low bone mass","volume":"26","author":"Filipponi","year":"2000","journal-title":"Bone"},{"key":"10.1016\/j.bone.2004.01.008_BIB4","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1359\/jbmr.1997.12.10.1700","article-title":"Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis","volume":"12","author":"Khan","year":"1997","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2004.01.008_BIB5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0169-6009(91)90129-N","article-title":"Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis","volume":"15","author":"Passeri","year":"1991","journal-title":"Bone Miner."},{"key":"10.1016\/j.bone.2004.01.008_BIB6","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/BF01623227","article-title":"Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause","volume":"4","author":"Thi\u00e9baud","year":"1994","journal-title":"Osteoporosis Int."},{"key":"10.1016\/j.bone.2004.01.008_BIB7","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0140-6736(83)91465-4","article-title":"Renal failure associated with intravenous diphosphonates","volume":"1","author":"Bounameaux","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2004.01.008_BIB8","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0169-6009(91)90131-I","article-title":"Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemia","volume":"15","author":"Dumon","year":"1991","journal-title":"Bone Miner."},{"key":"10.1016\/j.bone.2004.01.008_BIB9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","article-title":"Toxic acute tubular necrosis following treatment with zoledronate (Zometa)","volume":"64","author":"Markowitz","year":"2003","journal-title":"Kidney Int."},{"key":"10.1016\/j.bone.2004.01.008_BIB10","first-page":"990","article-title":"Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats","volume":"29","author":"Bauss","year":"2002","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bone.2004.01.008_BIB11","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1359\/jbmr.1999.14.10.1768","article-title":"Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties","volume":"14","author":"Monier-Faugere","year":"1999","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2004.01.008_BIB12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S8756-3282(02)00923-7","article-title":"Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys","volume":"32","author":"Smith","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.bone.2004.01.008_BIB13","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/jbmr.5650060915","article-title":"BM 21.0955, a potent new bisphosphonate to inhibit bone resorption","volume":"6","author":"M\u00fchlbauer","year":"1991","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2004.01.008_BIB14","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/jbmr.5650110506","article-title":"Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection","volume":"11","author":"Pecherstorfer","year":"1996","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2004.01.008_BIB15","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000026952","article-title":"The new bisphosphonate ibandronate in the treatment of tumor-induced hypercalcemia","volume":"22","author":"Herrmann","year":"1999","journal-title":"Onkologie"},{"key":"10.1016\/j.bone.2004.01.008_BIB16","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1996.14.1.268","article-title":"Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy","volume":"14","author":"Pecherstorfer","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bone.2004.01.008_BIB17","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0002-9343(97)00249-0","article-title":"Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis","volume":"103","author":"Thi\u00e9baud","year":"1997","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bone.2004.01.008_BIB18","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","author":"Chesnut","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2004.01.008_BIB19","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.bone.2004.01.007","article-title":"Efficacy and safety of ibandronate given by intravenous injection once every 3 months","volume":"34","author":"Adami","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.bone.2004.01.008_BIB20","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1136\/ard.62.10.969","article-title":"Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis","volume":"62","author":"Stakkestad","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bone.2004.01.008_BIB21","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/rheumatology\/keg205","article-title":"Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis","volume":"42","author":"Ringe","year":"2003","journal-title":"Rheumatology"},{"key":"10.1016\/j.bone.2004.01.008_BIB22","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jc.85.1.231","article-title":"Antifracture efficacy of antiresorptive agents are related to changes in bone density","volume":"85","author":"Wasnich","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2004.01.008_BIB23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0002-9343(01)01124-X","article-title":"Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs","volume":"112","author":"Cummings","year":"2002","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bone.2004.01.008_BIB24","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328204000249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328204000249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,9]],"date-time":"2019-02-09T20:28:41Z","timestamp":1549744121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328204000249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["S8756328204000249"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2004.01.008","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2004,5]]}}}